# Ablation Combined With PD-1 in HCC: Phase II Study

> **NCT04652440** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** PD-1 monoclonal antibody
- **PROCEDURE:** Radiofequencey or microwave ablation

## Key facts

- **NCT ID:** NCT04652440
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-15
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04652440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04652440, "Ablation Combined With PD-1 in HCC: Phase II Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04652440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*